• Accelero_Spring_2017_1.jpg
  • Accelero_Spring_2017_2.jpg
  • Accelero_Spring_2017_3.jpg
  • Accelero_Spring_2017_4.jpg
  • Accelero_Spring_2017_5.jpg
  • Accelero_Spring_2017_6.jpg
  • Accelero_Spring_2017_7.jpg
  • Accelero_Spring_2017_8.jpg
  • Accelero_Spring_2017_9.jpg

Accelero Bioanalytics´ founder is pleased to be selected as a co-author for a first-in-human phase I clinical trial investigating a siRNA drug product formulation: Schultheis B et al, J Clin Oncol 2014 Nov 17 (Pubmed, J Clin Oncol).

During his time as a bioanalytical scientist at the study sponsor´s site, the founder was responsible for pharmacokinetic assay development and detection of in vivo RNA interference in cynomolgus monkey lung tissue.

Accelero´s founder was subsequently involved in the pharmacokinetic sample analysis as well as the determination of relevant pharmacodynamic parameters like inflammation markers in human serum and plasma.